Teleflex Inc.
- TFX · NYSE
- Surgical & Medical Instruments & Apparatus
- Wayne, PA
- 15,500 employees
- CIK 0000096943
Updated from SEC filings through
Top things to know
Executives
- Jason R. Weidman President and CEO 4, 2026-06-09
- Stuart A. Randle Interim President and Chief Executive Officer 8-K, 2026-06-09
-
John Deren Executive Vice President & CFO 4, 2026-03-05 - John R. Deren Executive Vice President and Chief Financial Officer 10-K, 2026-02-27
-
Daniel V. Logue Corporate Vice President, General Counsel & Secretary 8-K, 2026-09-09 - Dominik Michal Reterski Corporate Vice President, QARA 3, 2026-04-13
What leadership is saying
“We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Teleflex Inc is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Wayne, PA. It trades as TFX on NYSE. Revenue was $2.0B in the fiscal year ending December 31, 2025, +17.2% from the year before. It reported about 15,500 employees. Jason R. Weidman is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0B 10-K, 2026-02-27 | $1.7B 10-K, 2026-02-27 | $1.7B 10-K, 2026-02-27 | $2.8B 10-K, 2025-02-28 | $2.8B 10-K, 2024-02-23 |
| Operating income | $118M 10-K, 2026-02-27 | $104M 10-K, 2026-02-27 | $259M 10-K, 2026-02-27 | $500M 10-K, 2025-02-28 | $628M 10-K, 2024-02-23 |
| SG&A | $720M 10-K, 2026-02-27 | $675M 10-K, 2026-02-27 | $623M 10-K, 2026-02-27 | $864M 10-K, 2025-02-28 | $860M 10-K, 2024-02-23 |
| Net income | -$906M 10-K, 2026-02-27 | $69.7M 10-K, 2026-02-27 | $356M 10-K, 2026-02-27 | $363M 10-K, 2025-02-28 | $485M 10-K, 2024-02-23 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jason R. Weidman | President and CEO | 4, 2026-06-09 |
| Stuart A. Randle | Interim President and Chief Executive Officer | 8-K, 2026-06-09 |
| John Deren Executive Vice President and Chief Financial Officer at Teleflex | Executive Vice President & CFO | 4, 2026-03-05 |
| John R. Deren | Executive Vice President and Chief Financial Officer | 10-K, 2026-02-27 |
| Daniel V. Logue | Corporate Vice President, General Counsel & Secretary | 8-K, 2026-09-09 |
| James P. Winters Corporate VP Manufacturing and Supply Chain at Teleflex Incorporated | Named in proxy bio: Corporate Vice President, Manufacturing and Supply Chain | DEF 14A, 2026-04-13 |
| Dominik Michal Reterski | Corporate Vice President, QARA | 3, 2026-04-13 |
 Cameron P. Hicks | Corp. VP & Chief HR Officer | 4, 2026-03-05 |
| James Winters | Corp VP, Mfg and Supply | 4, 2026-03-05 |
| Sean M. Salmon | director | 8-K, 2026-09-09 |
| Andrew A. Krakauer | Board member (per proxy) bio: director | DEF 14A, 2026-04-13 |
| Candace H. Duncan | Board member (per proxy) bio: director | DEF 14A, 2026-04-13 |
| Gretchen R. Haggerty | Board member (per proxy) bio: director | DEF 14A, 2026-04-13 |
| Jaewon Ryu, M.D. | Board member (per proxy) bio: director | DEF 14A, 2026-04-13 |
| Michael J. Tokich | Board member (per proxy) bio: new director nominee | DEF 14A, 2026-04-13 |
| Neena M. Patil | Board member (per proxy) bio: director | DEF 14A, 2026-04-13 |
What Teleflex Inc does
Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 39.7 million (as of November 3, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $2.3B (as of June 29, 2025) | 10-K, February 27, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting April 1, 2026 (filed April 13, 2026) | DEF 14A, April 13, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 6, 2025 | Gretchen R. Haggerty Director | Buy | 500 | $57K | Form 4, August 7, 2025 |
| August 5, 2025 | Stuart A. Randle Director | Buy | 1,000 | $116K | Form 4, August 7, 2025 |
| August 5, 2025 | Andrew A. Krakauer Director | Buy | 1,000 | $115K | Form 4, August 7, 2025 |
| August 5, 2025 | Liam Kelly Chairman, President & CEO | Buy | 1,500 | $173K | Form 4, August 7, 2025 |
| August 5, 2025 | Jaewon Ryu Director | Buy | 1,500 | $173K | Form 4, August 7, 2025 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-07
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-03
- Item 2.01 Completion of acquisition or disposition of assets
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-15
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-06-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-02
- Item 8.01 Other events
- 8-K filed 2026-06-01
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-05-27
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
Frequently asked questions about Teleflex Inc
- What does Teleflex Inc do?
- In its own words, from Item 1 of its 10-K: "Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors."
- What is Teleflex Inc's revenue?
- $2.0B for the fiscal year ending December 31, 2025, from its 10-K filed February 27, 2026.
- Is Teleflex Inc profitable?
- Teleflex Inc reported net income of -$906M for the fiscal year ending December 31, 2025.
- How many employees does Teleflex Inc have?
- About 15,500 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Teleflex Inc?
- Jason R. Weidman, President and CEO, as named in a 4 filed June 9, 2026.
- Who is the CFO of Teleflex Inc?
- John Deren, Executive Vice President & CFO, as named in a 4 filed March 5, 2026.
- Where is Teleflex Inc headquartered?
- Wayne, PA.
- What is Teleflex Inc's stock ticker?
- TFX on NYSE.
- What industry is Teleflex Inc in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Teleflex Inc's website?
- teleflex.com.
- When does Teleflex Inc report earnings next?
- December 24, 2026. Source: estimate_8k_pattern.
- Is Teleflex Inc a public company?
- Yes. Teleflex Inc files with the SEC under CIK 0000096943 and trades as TFX.
- Who audits Teleflex Inc?
- PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Teleflex Inc are outstanding?
- 39.7 million shares as of November 3, 2026, from its 10-Q filed November 5, 2026.
- What is Teleflex Inc's public float?
- $2.3B as of June 29, 2025, as reported on the cover of its 10-K filed February 27, 2026.
- How many business segments does Teleflex Inc report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Teleflex Inc's annual shareholder meeting?
- April 1, 2026, per its proxy statement (DEF 14A) filed April 13, 2026.
- Have Teleflex Inc insiders traded stock recently?
- Since August 5, 2025, officers and directors reported 0 open-market sales and 5 purchases worth about $634K on Forms 4 and 5. The most recent: Gretchen R. Haggerty (Director) bought 500 shares on August 6, 2025.